Bartlett DL - Search Results

1

High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy.

Dong Xda E, Ito N, Lotze MT, Demarco RA, Popovic P, Shand SH, Watkins S, Winikoff S, Brown CK, Bartlett DL, Zeh HJ 3rd. Dong Xda E, et al. Among authors: bartlett dl. J Immunother. 2007 Sep;30(6):596-606. doi: 10.1097/CJI.0b013e31804efc76. J Immunother. 2007. PMID: 17667523

2

Intraarterial calcium stimulation and intraoperative ultrasonography in the localization and resection of insulinomas.

Brown CK, Bartlett DL, Doppman JL, Gorden P, Libutti SK, Fraker DL, Shawker TH, Skarulis MC, Alexander HR. Brown CK, et al. Among authors: bartlett dl. Surgery. 1997 Dec;122(6):1189-93; discussion 1193-4. doi: 10.1016/s0039-6060(97)90226-9. Surgery. 1997. PMID: 9426437

3

Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor-independent mechanisms.

Alexander HR, Brown CK, Bartlett DL, Libutti SK, Figg WD, Raje S, Turner E. Alexander HR, et al. Among authors: bartlett dl. Clin Cancer Res. 1998 Oct;4(10):2357-62. Clin Cancer Res. 1998. PMID: 9796965

4

Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy.

Puhlmann M, Gnant M, Brown CK, Alexander HR, Bartlett DL. Puhlmann M, et al. Among authors: bartlett dl. Hum Gene Ther. 1999 Mar 1;10(4):649-57. doi: 10.1089/10430349950018724. Hum Gene Ther. 1999. PMID: 10094208

5

Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant.

Puhlmann M, Brown CK, Gnant M, Huang J, Libutti SK, Alexander HR, Bartlett DL. Puhlmann M, et al. Among authors: bartlett dl. Cancer Gene Ther. 2000 Jan;7(1):66-73. doi: 10.1038/sj.cgt.7700075. Cancer Gene Ther. 2000. PMID: 10678358

6

Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers.

Zeh HJ, Bartlett DL. Zeh HJ, et al. Among authors: bartlett dl. Cancer Gene Ther. 2002 Dec;9(12):1001-12. doi: 10.1038/sj.cgt.7700549. Cancer Gene Ther. 2002. PMID: 12522439 Review.

7

Pancreaticoduodenectomy in the presence of superior mesenteric venous obstruction.

Koniaris LG, Staveley-O'Carroll KF, Zeh HJ, Perez E, Jin XL, Maley WR, Zabari G, Bartlett DL, Khanna A, Franceschi D, Schoeniger LO. Koniaris LG, et al. Among authors: bartlett dl. J Gastrointest Surg. 2005 Sep-Oct;9(7):915-21. doi: 10.1016/j.gassur.2005.04.005. J Gastrointest Surg. 2005. PMID: 16137584

8

Natural killer-dendritic cell cross-talk in cancer immunotherapy.

Kalinski P, Mailliard RB, Giermasz A, Zeh HJ, Basse P, Bartlett DL, Kirkwood JM, Lotze MT, Herberman RB. Kalinski P, et al. Among authors: bartlett dl. Expert Opin Biol Ther. 2005 Oct;5(10):1303-15. doi: 10.1517/14712598.5.10.1303. Expert Opin Biol Ther. 2005. PMID: 16197336 Review.

9

The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2.

Guo ZS, Naik A, O'Malley ME, Popovic P, Demarco R, Hu Y, Yin X, Yang S, Zeh HJ, Moss B, Lotze MT, Bartlett DL. Guo ZS, et al. Among authors: bartlett dl. Cancer Res. 2005 Nov 1;65(21):9991-8. doi: 10.1158/0008-5472.CAN-05-1630. Cancer Res. 2005. PMID: 16267024

10

High mobility group B1 protein suppresses the human plasmacytoid dendritic cell response to TLR9 agonists.

Popovic PJ, DeMarco R, Lotze MT, Winikoff SE, Bartlett DL, Krieg AM, Guo ZS, Brown CK, Tracey KJ, Zeh HJ 3rd. Popovic PJ, et al. Among authors: bartlett dl. J Immunol. 2006 Dec 15;177(12):8701-7. doi: 10.4049/jimmunol.177.12.8701. J Immunol. 2006. PMID: 17142771

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

410 results

Search Page

Filters